FOI REF: 26/750

East Sussex Healthcare NHS Trust

6th November 2026

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am writing to request information regarding the treatment of cancers in secondary care.

It would be a great help if you could answer the questions below in relation to the number of patients treated with specific medicines between the first of July and the thirtieth of September of this year, or the latest three-month period for which data is available. Please include data for all hospitals managed by your Trust.

1. **How many patients were treated in <u>total, regardless of diagnosis</u>, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026, or latest 3-month period available?**

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	67
1.2 Alpelisib (Piqray)	2
1.3 Camizestrant (Etcamah)	0
1.4 Capivasertib (Truqap)	3
1.5 Elacestrant (Orserdu)	11
1.6 Elinzanetant (Lynkuet)	0
1.7 Fulvestrant (fulvestrant or Faslodex)	60
1.8 Inavolisib (Inaqovi)	0
1.9 Imlunestrant (Inluriyo)	0
1.10 Olaparib (Lynparza)	16
1.11 Palbociclib (Ibrance)	36
1.12 Ribociclib (Kisqali)	162

Name of medicine	Number patients treated
1.13 Talazoparib (Talzenna)	0
1.14 Vepdegestrant (Veppanu)	0

2. **How many patients were treated in <u>total, regardless of diagnosis</u>, with the following products in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
2.1 Pertuzumab (Perjeta)	2
2.2 Pertuzumab with Trastuzumab (Phesgo)	1
2.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	73
2.4 Trastuzumab Deruxtecan (Enhertu)	5
2.5 Trastuzumab Emtansine (Kadcyla)	16
2.6 Tucatinib (Tukysa)	0
2.7 Neratinib (Nerlynx)	0

3. **How many patients were treated specifically for <u>breast cancer</u> (ICD-10 codes = C50*, D05) in the 3 months between 1st July 2026 and the end of September 2026?**

Breast Cancer	Number patients treated
3.1 Olaparib - All types of breast cancer	3
3.2 Talazoparib – All types of breast cancer	0
3.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) - All types of breast cancer	68
3.4 Trastuzumab Deruxtecan (Enhertu) - All types of breast cancer	5

4. **How many patients received the following medicines with <u>curative treatment intent</u> in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available?**

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios)	2
4.2 Ribociclib (Kisqali)	31
4.3 Pertuzumab (Perjeta)	0

Name of combination or monotherapy	Number patients treated
4.4 Pertuzumab with Trastuzumab (Phesgo)	0
4.5 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	35
4.6 Trastuzumab Emtansine (Kadcyla)	9

5. **How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available?**

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
5.1 Olaparib (Lynparza)	3	9	12
5.2 Pertuzumab (Perjeta)	1	0	1
5.3 Pertuzumab with Trastuzumab (Phesgo)	1	0	1
5.4 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	32	22	54
5.5 Trastuzumab Emtansine (Kadcyla)	1	0	1

6. **How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period for which data are available?**

Treatment intent	Number patients treated
6.1 HER2+ve Breast Cancer	3
6.2 HER2-low Breast Cancer	2

7. **How many patients were treated with the following medicines in combination in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available?**

Name of combination or monotherapy	Number patients treated
7.1 Pertuzumab + Trastuzumab (Phesgo) + Taxane (Docetaxel or Paclitaxel)	31
7.2 Pertuzumab (Perjeta) + Trastuzumab Deruxtecan (Enhertu)	0

8. How many submissions for funding were made to the Cancer Drugs Fund for trastuzumab deruxtecan (Enhertu) with the following BlueTeq codes in the 3 months between 1st July 2026 and the end of September 2026, or latest 3-month period available?

CDF BlueTeq code	Description	Number submissions
TRAD1	"Trastuzumab Deruxtecan (Enhertu) for HER2+ve unresectable, locally advanced or metastatic breast cancer in patients who have received 2 or more anti-HER2 therapies and received trastuzumab emtansine (Kadcyla)"	8
TRAD2	"Trastuzumab Deruxtecan (Enhertu) for HER2+ve unresectable, locally advanced or metastatic breast cancer in patients who have received 1 or more anti-HER2 therapies and received trastuzumab emtansine (Kadcyla)"	10
TRAD3	"Trastuzumab Deruxtecan (Enhertu) for HER2-low metastatic or unresectable breast cancer after chemotherapy"	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm